ClinicaliQ Trial Snapshot
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting • Phase III • Gastroenterology • NCT06588855.
- A new drug called Afimkibart is being tested to see if it safely treats moderate to severe ulcerative colitis better than placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC). Conditions: Moderately to Severely Active Ulcerative Colitis Interventions: Afimkibart, Placebo Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 350 participants